Using Circulating Tumor DNA to Guide Targeted Maintenance Therapy in Women With High-Grade Serous Ovarian Cancer

What this Trial Is About

Researchers are conducting a prospective observational trial involving patients newly diagnosed and treated for high-grade serous ovarian cancer. The study aims to evaluate circulating tumor DNA ctDNA as a novel molecular marker to predict the effectiveness of PARP inhibitors and to detect early disease recurrence. This research is led by Xinhua Hospital, Shanghai Jiao Tong University School of Medicine. Participants will receive first-line maintenance treatment with PARP inhibitors following traditional chemotherapy. The study collects plasma samples at multiple points before surgery, after chemotherapy, during targeted maintenance therapy, and if disease progresses. These samples are analyzed for ctDNA-specific genomes alongside clinical data to assess treatment response. During the trial, participants will undergo regular plasma collection and clinical evaluations. Researchers will monitor progression-free survival approximately 36 months after starting PARP inhibitors, with secondary measures including overall survival over 5 years and objective response rates at 36 months. This thorough monitoring helps track treatment effects and disease status over time.

CtDNA as a Novel Biomarker of Treatment Efficacy in Patients With Ovarian Cancer